Patient?derived xenograft (PDX) models have high consistency with their primary tumors in terms of genetics, pathology, and biological characteristics. Being perfect in clinical response to drugs, this model shows a good prospect in tumor individualized treatment. It can be used to screen tumor target drug and effectively guide clinical medication. In this review, we focused on the evaluation strategy of PDX models based on chemotherapeutics screening, summarized the standards and quality control requirements of PDX models. We proposed four different ways to evaluate the traceability of models, including histological detection, sequencing analysis, tumor specific marker determination and short tandem repeat (STR) testing. Furthermore, chemotherapeutics effect can be evaluated by measuring drug toxicity, changes of tumor volume and establishment of TGD mathematical model. All these method applied in the PDX models provide perfect strategy for guiding tumor individualized treatment.